Neonatal brain injury and systemic inflammation: Modulation by activated protein C ex vivo

Clinical and Experimental Immunology

Volumn 179, Issue 3, 2015, Pages 477-484

  Eliwan, H O ^a,b,c,d   Watson, R W G ^b   Aslam, S ^a   Regan, I ^e   Philbin, B ^e   O'Hare, F M ^a,b,c   O'Neill, A ^b   Preston, R ^c   Blanco, A ^b   Grant, T ^b   Nolan, B ^e   Smith, O ^e   Molloy, E J ^a,b,c,d,e,f  

^a NATIONAL MATERNITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c NATIONAL CHILDREN S RESEARCH CENTRE   (Ireland)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^e OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^f TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

CD11b; Neonatal encephalopathy; Protein C; Reactive oxygen intermediates; Toll like receptor 4

Indexed keywords

ACTIVATED PROTEIN C; CD11B ANTIGEN; LIPOPOLYSACCHARIDE; PROTEIN C; TOLL LIKE RECEPTOR 4; ANTICOAGULANT AGENT; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; TLR4 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; BRAIN DISEASE; BRAIN INJURY; CELL ACTIVATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; INFANT; INFLAMMATION; MALE; MONOCYTE; NEONATAL ENCEPHALOPATHY; NEUTROPHIL; NEWBORN DISEASE; PRIORITY JOURNAL; TISSUE INJURY; ADULT; BRAIN; CELL CULTURE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MENTAL RETARDATION, X-LINKED; METABOLISM; NEWBORN; PATHOLOGY; UPREGULATION; YOUNG ADULT;

ADULT; ANTICOAGULANTS; ANTIGENS, CD11B; BRAIN; CELLS, CULTURED; FEMALE; HUMANS; INFANT, NEWBORN; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MENTAL RETARDATION, X-LINKED; MONOCYTES; NEUROPROTECTIVE AGENTS; NEUTROPHILS; PROTEIN C; REACTIVE OXYGEN SPECIES; TOLL-LIKE RECEPTOR 4; UP-REGULATION; YOUNG ADULT;

EID: 84922769051     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12453     Document Type: Article

References (44)

1. Badawi N, Keogh JM, Dixon G, Kurinczuk JJ. Developmental outcomes of newborn encephalopathy in the term infant. Indian J Pediatr 2001; 68:527-530.
2. Yoon BH, Jun JK, Romero R, Park KH, Gomez R, Choi JH. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1β, and tumor necrosis factor-α), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 1997; 177:19-26.
3. Nelson KB, Dambrosia JM, Grether JK, Phillips TM. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998; 44:665-675.
4. Wu YW, Escobar GJ, Grether JK, Croen LA, Greene JD, Newman TB. Chorioamnionitis and cerebral palsy in term and near-term infants. JAMA 2003; 290:2677-2684.
5. Hermansen MC, Hermansen MG. Perinatal infections and cerebral palsy. Clin Perinatol 2006; 33:315-333.
6. Barks JDE, Liu YQ, Shangguan Y, Li J, Pfau J, Silverstein FS. Impact of indolent inflammationon neonatal hypoxic-ischemic brain injury in mice. Int J Dev Neurosci 2008; 26:57-65.
7. Eklind S, Mallard C, Leverin AL, Gilland E, Blomgren K, Mattsby-Baltzer I. Bacterial endotoxin sensitizes the immature brain to hypoxic-ischaemic injury. Eur J Neurosci 2001; 13:1101-1106.
8. McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci 2007; 27:4403-4412.
9. Elkind MS, Cheng J, Rundek T, Boden-Albala B, Sacco RL. Leukocyte count predicts outcome after ischemic stroke: the Northern Manhattan Stroke Study. J Stroke Cerebrovasc Dis 2004; 13:220-227.
10. Wang X. Investigational anti-inflammatory agents for the treatment of ischemic brain injury. Expert Opin Investig Drugs 2005; 14:393-409.
11. Yilmaz G, Granger DN. Cell adhesion molecules and ischemic stroke. Neurol Res 2008; 30:783-793.
12. Morkos AA, Hopper AO, Deming DD etal. Elevated total peripheral leukocyte count may identify risk for neurological disability in asphyxiated term neonates. J Perinatol 2007; 27:365-370.
13. Hudome S, Palmer C, Roberts RL, Mauger D, Housman C, Towfighi J. The role of neutrophils in the production of hypoxic-ischemic brain injury in the neonatal rat. Pediatr Res 1997; 41:607-616.
14. Liu F, McCullough LD. Inflammatory responses in hypoxic ischemic encephalopathy. Acta Pharmacol Sin 2013; 34:1121-1130.
15. Molloy EJ, O'Neill AJ, Doyle BT etal. Effects of heat shock and hypoxia on neonatal neutrophil lipopolysaccharide responses: altered apoptosis, Toll-like receptor-4 and CD11b expression compared with adults. Biol Neonate 2006; 90:34-39.
16. Zhang L, Zhang ZG, Zhang RL, Lu M, Krams M, Chopp M. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke 2003; 34:1790-1795.
17. Becker KJ. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke. Curr Med Res Opin 2002; 18:18-22.
18. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Izasoation I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007; 115:1599-1608.
19. Smith JA. Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol 1994; 56:672-686.
20. Kontos CD, Wei EP, Williams JI, Kontos HA, Povlishock JT. Cytochemical detection of superoxide in cerebral inflammation and ischemia in vivo. Am J Physiol 1992; 263:H1234-1242.
21. Defraigne JO, Detry O, Pincemail J etal. Direct evidence of free radical production after ischaemia and reperfusion and protective effect of desferrioxamine: ESR and vitamin E studies. Eur J Vasc Surg 1994; 8:537-543.
22. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12:135-145.
23. Bernard GR, Vincent JLV, Laterre PF etal. PROWESS study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
24. Yesilirmak DC, Kumral A, Tugyan K, Cilaker S, Baskin H, Yilmaz O. Effects of activated protein C on neonatal hypoxic ischemic brain injury. Brain Res 2008; 1210:56-62.
25. Yesilirmak DC, Kumral A, Baskin H etal. Activated protein C reduces endotoxin-induced white matter injury in the developing rat brain. Brain Res 2007; 20:14-23.
26. Huang CC, Wang ST, Chang YC, Lin KP, Wu PL. Measurement of the urinary lactate: creatinine ratio for the early identification of newborn infants at risk for hypoxic-ischemic encephalopathy. N Engl J Med 1999; 341:328-335.
27. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol 1976; 33:696-705.
28. Barkovich AJ, Hajnal BL, Vigneron D etal. Prediction of neuromotor outcome in perinatal asphyxia: evaluation of MR scoring systems. Am J Neuroradiol 1998; 19:143-149.
29. Galley HF, El Sakka NE, Webster NR etal. Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions. Br J Anaesth 2008; 100:815-819.
30. Smith JA, Wiedemann MJ. Further characterization of the neutrophil oxidative burst by flow cytometry. J Immunol Methods 1993; 3:261-268.
31. Molloy EJ, O'Neill AJ, Grantham JJ etal. Labor induces a maternal inflammatory response syndrome. Am J Obstet Gynecol 2004; 190:448-455.
32. Molloy EJ, O'Neill AJ, Grantham-Sloan JJ, Webb DW, Watson RW. Maternal and neonatal lipopolysaccharide and Fas responses are altered by antenatal risk factors for sepsis. Clin Exp Immunol 2008; 151:244-250.
33. Molloy EJ, O'Neill AJ, Grantham-Sloan JJ etal. Neonatal encephalopathy is associated with altered perinatal systemic neutrophil apoptosis. Am J Perinatol 2007; 24:525-530.
34. Winerdal M, Winerdal ME, Kinn J, Urmaliya V, Winqvist O, Ådén U. Long lasting local and systemic inflammation after cerebral hypoxic ischemia in newborn mice. PLOS ONE 2012; 7:e36422.
35. Morrison H, McKee D, Ritter L. Systemic neutrophil activation in a mouse model of ischemic stroke and reperfusion. Biol Res Nurs 2011; 13:154-163.
36. Lehnard S, Lachance C, Patrizi S etal. The Toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 2002; 22:2478-2486.
37. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007; 104:13798-13803.
38. Wang YC, Wang PF, Fang H, Chen J, Xiong XY, Yang QW. Toll-like receptor 4 antagonist attenuates intracerebral hemorrhage-induced brain injury. Stroke 2013; 44:2545-2552.
39. Molloy EJ, O'Neill AJ, Grantham JJ etal. Labor promotes neonatal neutrophil survival and lipopolysaccharide responsiveness. Pediatr Res 2004; 56:99-103.
40. Christiaans SC, Wagener BM, Esmon CT, Pittet JF. Protein C and acute inflammation: a clinical and biological perspective. Am J Physiol Lung Cell Mol Physiol 2013; 305:455-466.
41. Marti-Carvaial AJ, Sola I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2011; (4): CD004388. doi: 10.1002/14651858.
42. Mosnier LO, Yanq XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007; 282:33022-33033.
43. Kerschen EJ, Fernandez JA, Cooley BC etal. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204:2439-2448.
44. Zlokovic BV, Griffin JH. Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci 2011; 34:198-209.